Genmab A/S (GMAB) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Genmab A/s.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.496 Hello and welcome to the GenMAP first half 2025 financial results conference 00:00:05.496 -- 00:00:10.080 call. As a reminder, this conference call is being recorded. 00:00:10.080 -- 00:00:15.065 During this telephone conference, you may be presented with forward-looking statements 00:00:15.065 -- 00:00:20.010 that include words such as beliefs, anticipates, plans, or expects. 00:00:20.010 -- 00:00:25.135 Actual results may differ materially, for example, as a result of delayed or 00:00:25.135 -- 00:00:30.823 unsuccessful development projects. GenMav is not under any obligation 00:00:30.823 -- 00:00:35.888 to update statements regarding the future, nor to confirm such statements in relation 00:00:35.888 -- 00:00:39.492 to actual results, unless this is required by law. 00:00:39.492 -- 00:00:44.658 Please also note that GenMav may hold your personal data as indicated by you as 00:00:44.658 -- 00:00:49.843 part of our investor relations outreach activities in order to update you on GenMav 00:00:49.843 -- 00:00:54.929 going forward. Please refer to our website for more information on GenMav and 00:00:54.929 -- 00:00:59.155 our privacy policy. I would now like to hand the conference over to our first speaker 00:00:59.155 -- 00:01:03.798 today, Jan van der Winkel. Please go ahead. 00:01:03.820 -- 00:01:08.125 Hello, and welcome to our financial results call for the first nine months of 2025. 00:01:08.125 -- 00:01:09.927 With 00:01:09.927 -- 00:01:13.752 me today is our Chief Financial Officer, Anthony Pagano, 00:01:13.752 -- 00:01:19.598 our Chief Commercial Officer, Brad Bailey, and our Chief Medical Officer, Taya Mahdi. 00:01:19.598 -- 00:01:25.022 And for the Q&A, we will be joined by our Chief Development Officer, Judith Klimowski. ...